Cardiac drug safety is a major concern and one of the sticking points throughout cardiac drug development. Therefore, improving in vitro assays at the early phases of drug development is critical in preventing late-stage failure.
In vitro cell cultures are a powerful models for the accurate analysis of human heart disorders and therefore suitable to perform cardiotoxicity assays. Many of these disorders are the result of subtle changes to cardiomyocyte excitability, contractility, or both. Our products aim to provide our customers with powerful tool for accurately measuring changes in depolarization, repolarization, and, indeed, detecting drug-related adverse responses.
Our products cover two main application areas:
| Cardiac drug safety | Stem-cell derived cardiac differentiation |
|---|---|
| Acute and chronic protocols for Action Potential (AP) recordings from the same electrode over many weeks. | Evaluation of cell morphology, contraction and organization. |
| Prediction of early cardiotoxicity on both healthy and diseased cells. | Tracking of APs at network level with single cell resolution. |
| Identification of cardiovascular issues at hit-to-lead stage of drug discovery and compounds optimization. | Evaluation of genetic-based disorders correlated to changes in the electrical activity propagation. |
| Already tested with several compounds form CiPA list (i.e. hERG block, Arrhythmia detection). | Optimization of protocols for differentiation of stem cells into cardiac cells. |
Massive action potential recordings and activity propagation analysis
The video shows exemplary cardiac action potentials on CMOS-MEA obtained with the FORESEE technology. The signals are overlaid on the map showing the propagation of the cardiac activity over the 4096 electrodes of the MEA.”.
FILL OUT THE FORM